Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Abiomed appoints CFO
From 2005 to 2008, Mr Bowen was vice president and CFO for GSI Group. At GSI Group, Mr Bowen led the consolidation of the company’s financial operations, implemented
From 2005 to 2008, Mr Bowen was vice president and CFO for GSI Group. At GSI Group, Mr Bowen led the consolidation of the company’s financial operations, implemented
Terms of the transaction provide for St Jude Medical to pay $138 million of the purchase price in December 2008, with the balance due in two subsequent payments
Replace is a double-blind, placebo-controlled trial that will randomize approximately 110 patients at over a dozen sites in the US, Canada and Europe. The primary objective is to
For this expansion, Galapagos receives a payment of E2 million cash from GlaxoSmithKline (GSK). This payment is in addition to the existing alliance terms, making the total alliance
According to the company, Actos directly targets insulin resistance, a condition characterized in patients with type 2 diabetes, by improving the sensitivity to insulin mainly in the muscles,
Acetazolamide for injection USP is indicated for adjunctive treatment of: edema due to congestive heart failure; drug-induced edema; centrencephalic epilepsies (petit mal, unlocalized seizures); chronic simple (open-angle) glaucoma,
The investigational new drug (IND) application seeks permission from the FDA to administer endometrial regenerative cells to 10 patients having specific inclusion or exclusion criteria and will focus
Under the terms of the amendment, Genmab is expected to receive a one-time payment of $4.5m from GlaxoSmithKline (GSK) upon the FDA’s acceptance for review of the filing of the
The company is planning to treat amyotrophic lateral sclerosis (ALS) patients through spinal injections of its stem cells via its patented human neural stem cell technology. ALS is
Dynavax said that it will continue to evaluate regulatory options for the development of Heplisav indicated for adults outside of the US and for the global end-stage renal